Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Objective: Structurally-improved GIP analogs were developed to determine precisely whether GIP receptor (GIPR) agonism or antagonism lowers body weight in obese mice. Methods: A series of peptide-based GIP analogs, including structurally diverse agonists and a long-acting antagonist, were generated...
Main Authors: | Piotr A. Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Perez-Tilve |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-02-01
|
Series: | Molecular Metabolism |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212877818311025 |
Similar Items
-
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
by: Jonathan E. Campbell
Published: (2021-04-01) -
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
by: Elizabeth A. Killion, et al.
Published: (2020-10-01) -
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
by: Ai, M., et al.
Published: (2022) -
Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
by: Gaurav Garg, et al.
Published: (2016-06-01) -
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
by: Sigrid Jall, et al.
Published: (2017-05-01)